MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Amgen Inc

Gesloten

SectorGezondheidszorg

310.17 1.39

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

305.51

Max

313.95

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.2B

627M

Verkoop

586M

9.1B

K/W

Sectorgemiddelde

41.156

63.778

EPS

5.31

Dividendrendement

3.06

Winstmarge

6.901

Werknemers

28,000

EBITDA

-517M

2.9B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+8.74% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.06%

2.39%

Volgende Winsten

1 mei 2025

Volgende dividenddatum

6 jun 2025

Volgende Ex Dividend datum

16 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

14B

167B

Vorige openingsprijs

308.78

Vorige sluitingsprijs

310.17

Nieuwssentiment

By Acuity

50%

50%

180 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Amgen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 feb 2025, 21:29 UTC

Winsten

Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains

30 okt 2024, 20:18 UTC

Winsten

Amgen Posts Higher 3Q Sales on Strong Demand

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb 2025, 21:02 UTC

Winsten

Amgen 4Q SAles Included $1.2 B of Sales From Rare Disease Products >AMGN

4 feb 2025, 21:01 UTC

Winsten

Amgen 4Q Worldwide Neulasta Sales $98M >AMGN

4 feb 2025, 21:01 UTC

Winsten

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

4 feb 2025, 21:01 UTC

Winsten

Amgen 4Q Worldwide Prolia Sales $1.17B >AMGN

4 feb 2025, 21:01 UTC

Winsten

Amgen Sees FY Rev $34.3B-$35.7B >AMGN

4 feb 2025, 21:01 UTC

Winsten

Amgen 4Q Adj EPS $5.31 >AMGN

4 feb 2025, 21:01 UTC

Winsten

Amgen 4Q Worldwide XGEVA Sales $561M >AMGN

4 feb 2025, 21:01 UTC

Winsten

Amgen Sees FY EPS $10.89-EPS $12.14 >AMGN

4 feb 2025, 21:01 UTC

Winsten

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

4 feb 2025, 21:01 UTC

Winsten

Amgen 4Q Rev $9.1B >AMGN

4 feb 2025, 21:01 UTC

Winsten

Amgen 4Q EPS $1.16 >AMGN

4 feb 2025, 21:01 UTC

Winsten

Amgen 4Q Net $627M >AMGN

28 jan 2025, 10:30 UTC

Top Nieuws

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

27 dec 2024, 07:00 UTC

Winsten

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

23 dec 2024, 15:04 UTC

Top Nieuws

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 dec 2024, 14:53 UTC

Top Nieuws

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

30 nov 2024, 12:00 UTC

Top Nieuws

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

26 nov 2024, 12:34 UTC

Top Nieuws

Amgen Drug Cut Weight in Closely Watched Study -- WSJ

4 nov 2024, 12:00 UTC

Top Nieuws

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

30 okt 2024, 20:02 UTC

Winsten

Amgen 3Q Sales From Rare Disease Products $1.2B >AMGN

30 okt 2024, 20:02 UTC

Winsten

Amgen CEO: Strong Growth in Sales, Earnings in 3Q Reflects Momentum Being Built Throughout Business>AMGN

30 okt 2024, 20:02 UTC

Winsten

Amgen: 2024 Buybacks Not to Exceed $500M>AMGN

30 okt 2024, 20:02 UTC

Winsten

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30 okt 2024, 20:02 UTC

Winsten

Amgen 3Q Worldwide Prolia Sales $1.05B >AMGN

30 okt 2024, 20:01 UTC

Winsten

Amgen 3Q Worldwide Enbrel Sales $825M >AMGN

30 okt 2024, 20:01 UTC

Winsten

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30 okt 2024, 20:01 UTC

Winsten

Amgen 3Q Worldwide Neulasta Sales $110M >AMGN

Peer Vergelijking

Prijswijziging

Amgen Inc Prognose

Koersdoel

By TipRanks

8.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 332.43 USD  8.74%

Hoogste 389 USD

Laagste 280 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Amgen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

18 ratings

11

Buy

6

Hold

1

Sell

Technische score

By Trading Central

304.35 / 315.75Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

180 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.